Previous 10 | Next 10 |
Boca Raton, Florida--(Newsfile Corp. - March 31, 2023) - NovelStem International Corp. (OTC Pink: NSTM ) , a development-stage company focused on the stem cell-based technology platform developed by Israel-based NewStem Ltd., today filed its Form 10-K for the year ended December 31, 2022....
NewStem joins MSK Innovation Hub in collaboration to advance stem cell-based diagnostics that will increase cancer treatment efficacy Jerusalem, Israel and Boca Raton, Florida--(Newsfile Corp. - December 14, 2022) - NovelStem International Corp. (OTC Pink: NSTM) , a biotechnology company ...
Boca Raton, Florida--(Newsfile Corp. - October 13, 2022) - NovelStem International Corp. (OTC Pink: NSTM ) , a development-stage company focused on the stem cell-based technology platform developed by 30%-owned, Israel-based NewStem Ltd., today announced that it has become an SEC-repor...
NewStem is the only company worldwide to develop therapeutics and diagnostics products based on haploid human embryonic stem cell research Jerusalem, Israel and Boca Raton, Florida--(Newsfile Corp. - April 11, 2022) - NovelStem International Corp. (OTC Pink: NSTM ) , a biotechnology...
Boca Raton, Florida--(Newsfile Corp. - February 15, 2022) - NovelStem International Corp. (OTC Pink: NSTM ) , a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned, Israel-based NewStem, Ltd., today reviewed progress regarding ongoing efforts...
Boca Raton, Florida and Jerusalem, Israel--(Newsfile Corp. - September 20, 2021) - NovelStem International Corp. (OTC Pink: NSTM ) , a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned Israel-based, NewStem, Ltd., announced that NewStem, al...
BOCA RATON, Fla. and JERUSALEM, Dec. 01, 2020 (GLOBE NEWSWIRE) -- NovelStem International Corp. (OTC Pink: NSTM ) , a biotechnology company focused on its stem cell-based technology platform, developed by Israel-based affiliate, NewStem, Ltd., announced today: ...
Screening of resistance diagnostics completed for twelve standard-of-care cancer treatments representing a significant portion of cancer treatment protocols. COVID-19 research collaboration initiated to identify genes regulating the virus in order to generate virus resistance...
BOCA RATON, Fla. and JERUSALEM, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- NovelStem International Corp. (OTC Pink: NSTM ), a biotechnology company focused on stem-cell-based diagnostic technology to aid the selection of cancer therapeutic agents being developed by its Israel-based ...
PITTSBURGH, May 16, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology in...
News, Short Squeeze, Breakout and More Instantly...
NovelStem International Corp Company Name:
NSTM Stock Symbol:
OTCMKTS Market:
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
Bitdeer Technologies Group (BTDR) is expected to report $0.11 for Q4 2023 BioForce Nanosciences Holdings Inc (BFNH) is expected to report for Q4 2023 Casino Guichard Perrachon ADR (CGUSY) is expected to report for quarter end 2023-12-31 Motorsport Games Inc. (MSGM) is expected to repo...
Tredegar Corporation (TG) is expected to report for quarter end 2023-12-31 Pharma-Bio Serv Inc (PBSV) is expected to report $0.02 for Q1 2024 Telos Corporation (TLS) is expected to report $-0.18 for Q4 2023 Coretec Group Inc (CRTG) is expected to report for quarter end 2023-12-31 ...